Free Trial

KalVista Pharmaceuticals (KALV) Stock Price, News & Analysis

KalVista Pharmaceuticals logo
$14.95 -0.11 (-0.73%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$14.90 -0.05 (-0.33%)
As of 07/8/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About KalVista Pharmaceuticals Stock (NASDAQ:KALV)

Key Stats

Today's Range
$14.81
$16.14
50-Day Range
$11.22
$15.06
52-Week Range
$7.30
$16.14
Volume
3.43 million shs
Average Volume
547,937 shs
Market Capitalization
$743.31 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$26.29
Consensus Rating
Buy

Company Overview

KalVista Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
85th Percentile Overall Score

KALV MarketRank™: 

KalVista Pharmaceuticals scored higher than 85% of companies evaluated by MarketBeat, and ranked 153rd out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    KalVista Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.11, and is based on 8 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    KalVista Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

  • Read more about KalVista Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for KalVista Pharmaceuticals are expected to grow in the coming year, from ($3.56) to ($2.90) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of KalVista Pharmaceuticals is -4.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of KalVista Pharmaceuticals is -4.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    KalVista Pharmaceuticals has a P/B Ratio of 3.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about KalVista Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    14.05% of the float of KalVista Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    KalVista Pharmaceuticals has a short interest ratio ("days to cover") of 8.5.
  • Change versus previous month

    Short interest in KalVista Pharmaceuticals has recently increased by 0.48%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    KalVista Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    KalVista Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    14.05% of the float of KalVista Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    KalVista Pharmaceuticals has a short interest ratio ("days to cover") of 8.5.
  • Change versus previous month

    Short interest in KalVista Pharmaceuticals has recently increased by 0.48%, indicating that investor sentiment is decreasing.
  • News Sentiment

    KalVista Pharmaceuticals has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 21 news articles for KalVista Pharmaceuticals this week, compared to 4 articles on an average week.
  • Search Interest

    12 people have searched for KALV on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    4 people have added KalVista Pharmaceuticals to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, KalVista Pharmaceuticals insiders have bought 14.22% more of their company's stock than they have sold. Specifically, they have bought $235,500.00 in company stock and sold $206,176.00 in company stock.

  • Percentage Held by Insiders

    10.50% of the stock of KalVista Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Read more about KalVista Pharmaceuticals' insider trading history.
Receive KALV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for KalVista Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

KALV Stock News Headlines

This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.
See More Headlines

KALV Stock Analysis - Frequently Asked Questions

KalVista Pharmaceuticals' stock was trading at $8.47 on January 1st, 2025. Since then, KALV shares have increased by 76.5% and is now trading at $14.95.

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) posted its earnings results on Thursday, December, 5th. The specialty pharmaceutical company reported ($0.91) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.01.

Shares of KALV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that KalVista Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Chevron (CVX) and Netflix (NFLX).

Company Calendar

Last Earnings
12/05/2024
Today
7/08/2025
Next Earnings (Estimated)
7/10/2025
Fiscal Year End
4/30/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:KALV
CIK
1348911
Employees
100
Year Founded
N/A

Price Target and Rating

High Price Target
$30.00
Low Price Target
$20.00
Potential Upside/Downside
+75.8%
Consensus Rating
Buy
Rating Score (0-4)
3.11
Research Coverage
9 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$126.64 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$4.86 per share
Price / Book
3.08

Miscellaneous

Free Float
44,496,000
Market Cap
$743.31 million
Optionable
Optionable
Beta
-0.04

Social Links

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

This page (NASDAQ:KALV) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners